DARZALEX® (daratumumab) Subcutaneous Formulation-Based Quadruplet Therapy Regimen Shows Significant Improvement in Outcomes for Patients with…


Daratumumab subcutaneous-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimen1

Link:
DARZALEX® (daratumumab) Subcutaneous Formulation-Based Quadruplet Therapy Regimen Shows Significant Improvement in Outcomes for Patients with...

Related Posts